Clinical Trials - March 30, 2015
Clanotech Drug Gets FDA Orphan Label
Clanotech AB’s candidate drug CLT-28643 has received orphan drug designation by the U.S. Food and Drug Administration (FDA) for prevention of scarring after glaucoma surgery. The European Medicines Agency (EMA) previously granted an orphan drug designation pertaining to the EU. The orphan drug designation is expected to significantly shorten future market approval processes and reinforce […]
